Carlos de Sousa
Chief Executive Officer at ULTIMOVACS ASA
Net worth: 11 011 $ as of 2024-03-30
Profile
Carlos de Sousa is currently the Chief Executive Officer at Ultimovacs ASA and Ultimovacs AB.
He is also a Principal at the University of Lisbon.
Previously, he served as the President & Chief Executive Officer at Mendus AB from 2016 to 2019.
He has also held positions such as Senior Director at Pfizer Saudi Ltd., Independent Director at Ectin Research AB, Chief Business Officer at Newron Pharmaceuticals SpA, Chief Business Officer & Senior Vice President at Zealand Pharma A, Vice President & Head-Commercial Licensing at Takeda A, Senior Vice President at Schwartz Pharma AG, Chief Business Officer at to-BBB Holding BV and to-BBB technologies BV, and Head-Negotiations at Novartis Pharma AG.
Dr. de Sousa holds a doctorate degree from the University of Lisbon and an MBA from The Leonard N Stern School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ULTIMOVACS AS
0.04% | 2022-12-30 | 14,906 ( 0.04% ) | 11 011 $ | 2024-03-30 |
Carlos de Sousa active positions
| Companies | Position | Start |
|---|---|---|
| ULTIMOVACS ASA | Chief Executive Officer | 2020-05-31 |
| University of Lisbon | Corporate Officer/Principal | - |
Ultimovacs AB
 Ultimovacs AB Pharmaceuticals: MajorHealth Technology Part of Ultimovacs ASA, Ultimovacs AB engages in pharmaceutical development. The CEO of the Swedish company is Carlos de Sousa. Ultimovacs was acquired by Ultimovacs ASA from Immuneed AB on August 29, 2018 for $6.05 million. | Chief Executive Officer | - |
Former positions of Carlos de Sousa
| Companies | Position | End |
|---|---|---|
| MENDUS AB | Chief Executive Officer | 2019-12-12 |
| ECTIN RESEARCH AB | Director/Board Member | - |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
| ZEALAND PHARMA A/S | Corporate Officer/Principal | - |
Training of Carlos de Sousa
| University of Lisbon | Doctorate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| ULTIMOVACS ASA | Health Technology |
| MENDUS AB | Health Technology |
| ECTIN RESEARCH AB | Health Technology |
| Private companies | 7 |
|---|---|
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
Schwartz Pharma AG
 Schwartz Pharma AG Pharmaceuticals: MajorHealth Technology Schwartz Pharma AG is a German company. | Health Technology |
to-BBB Holding BV
 to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Health Technology |
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
| Pfizer Saudi Ltd. | |
Ultimovacs AB
Ultimovacs AB Pharmaceuticals: MajorHealth Technology Part of Ultimovacs ASA, Ultimovacs AB engages in pharmaceutical development. The CEO of the Swedish company is Carlos de Sousa. Ultimovacs was acquired by Ultimovacs ASA from Immuneed AB on August 29, 2018 for $6.05 million. | Health Technology |
- Stock Market
- Insiders
- Carlos de Sousa
